PE20091224A1 - PHARMACEUTICAL COMPOSITION IN THE FORM OF ENCAPSULATED POWDERS INCLUDING ORLISTAT AND ITS PREPARATION PROCEDURE - Google Patents
PHARMACEUTICAL COMPOSITION IN THE FORM OF ENCAPSULATED POWDERS INCLUDING ORLISTAT AND ITS PREPARATION PROCEDUREInfo
- Publication number
- PE20091224A1 PE20091224A1 PE2007001452A PE2007001452A PE20091224A1 PE 20091224 A1 PE20091224 A1 PE 20091224A1 PE 2007001452 A PE2007001452 A PE 2007001452A PE 2007001452 A PE2007001452 A PE 2007001452A PE 20091224 A1 PE20091224 A1 PE 20091224A1
- Authority
- PE
- Peru
- Prior art keywords
- mixtures
- weight
- pharmaceutical composition
- sodium
- talc
- Prior art date
Links
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 title abstract 2
- 229960001243 orlistat Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000843 powder Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 239000004094 surface-active agent Substances 0.000 abstract 2
- 239000000454 talc Substances 0.000 abstract 2
- 229910052623 talc Inorganic materials 0.000 abstract 2
- 235000012222 talc Nutrition 0.000 abstract 2
- 229920002261 Corn starch Polymers 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 102000019280 Pancreatic lipases Human genes 0.000 abstract 1
- 108050006759 Pancreatic lipases Proteins 0.000 abstract 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 abstract 1
- 235000021355 Stearic acid Nutrition 0.000 abstract 1
- 239000006096 absorbing agent Substances 0.000 abstract 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 abstract 1
- 239000008116 calcium stearate Substances 0.000 abstract 1
- 235000013539 calcium stearate Nutrition 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000008120 corn starch Substances 0.000 abstract 1
- 238000010790 dilution Methods 0.000 abstract 1
- 239000012895 dilution Substances 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 abstract 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 abstract 1
- 229940116369 pancreatic lipase Drugs 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 abstract 1
- 229940079832 sodium starch glycolate Drugs 0.000 abstract 1
- 239000008109 sodium starch glycolate Substances 0.000 abstract 1
- 229920003109 sodium starch glycolate Polymers 0.000 abstract 1
- 235000019698 starch Nutrition 0.000 abstract 1
- 239000008117 stearic acid Substances 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UNA MEZCLA EN POLVO ENCAPSULADO DE ORLISTAT (TETRAHIDROLIPSTATINA) Y LOS SIGUIENTES EXCIPIENTES: 15 A 30% EN PESO DE UN AGENTE ABSORBENTE DE HUMEDAD SELECCIONADO DE LACTOSA MAGNESIO, MANITOL, ENTRE OTROS; 5 A 40% EN PESO DE UN AGENTE DE DILUCION SELECCIONADO DE CELULOSA MICROCRISTALINA, MANITOL GRANULAR O SUS MEZCLAS; 1 A 10% EN PESO DE UN DESINTEGRANTE SELECCIONADO DE ALMIDON GLICOLATO DE SODIO, ALMIDON DE MAIZ O SUS MEZCLAS; 1 A 10% EN PESO DE UN ANTIAGLOMERANTE SELECCIONADO DE POLIETILENGLICOL 4000, DIOXIDO DE SILICIO COLOIDAL, O SUS MEZCLAS; 0,5 A 2% EN PESO DE UN SURFACTANTE O TENSOACTIVO SELECCIONADO DE LAURILSULFATO DE SODIO, DIOCTILSULFOSUCCINATO DE SODIO, O SUS MEZCLAS; 0,5 A 2% DE UN GLIDANTE SELECCIONADO DE DIOXIDO DE SILICIO COLOIDAL, TALCO, ALMIDONES, ACIDO ESTEARICO O SUS MEZCLAS; 0,5 A 2% EN PESO DE UN LUBRICANTE SELECCIONADO DE TALCO, ESTEARATO DE MAGNESIO, ESTEARATO DE CALCIO O SUS MEZCLAS. DICHO PRINCIPIO ACTIVO ES INHIBIDOR DE LA LIPASA PANCREATICA, SIENDO DE UTILIDAD EN EL TRATAMIENTO DE LA OBESIDAD Y LA HIPERLIPIDEMIAIT REFERS TO A PHARMACEUTICAL COMPOSITION INCLUDING AN ENCAPSULATED POWDER MIXTURE OF ORLISTAT (TETRAHIDROLYPSTATIN) AND THE FOLLOWING EXCIPIENTS: 15 TO 30% BY WEIGHT OF A MOISTURE ABSORBING AGENT SELECTED FROM LACTOSE OR MANITHOLINE MAGNES; 5 TO 40% BY WEIGHT OF A SELECTED DILUTION AGENT OF MICROCRYSTALLINE CELLULOSE, GRANULAR MANNITOL OR THEIR MIXTURES; 1 TO 10% BY WEIGHT OF A DISINTEGRANT SELECTED FROM SODIUM STARCH GLYCOLATE, CORN STARCH OR THEIR MIXTURES; 1 TO 10% BY WEIGHT OF A SELECTED ANTIGLOMERANT OF POLYETHYLENE GLYCOL 4000, COLLOIDAL SILICON DIOXIDE, OR THEIR MIXTURES; 0.5 TO 2% BY WEIGHT OF A SURFACTANT OR SURFACTANT SELECTED FROM SODIUM LAURYLSULFATE, SODIUM DIOCTILSULFOSUCCINATE, OR THEIR MIXTURES; 0.5 TO 2% OF A SELECTED GLIDANT FROM COLLOIDAL SILICON DIOXIDE, TALC, STARCHES, STEARIC ACID OR THEIR MIXTURES; 0.5 TO 2% BY WEIGHT OF A SELECTED LUBRICANT OF TALC, MAGNESIUM STEARATE, CALCIUM STEARATE, OR THEIR MIXTURES. SAID ACTIVE PRINCIPLE IS AN INHIBITOR OF PANCREATIC LIPASE, BEING USEFUL IN THE TREATMENT OF OBESITY AND HYPERLIPIDEMIA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CL2007002287A CL53426B (en) | 2007-08-06 | 2007-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20091224A1 true PE20091224A1 (en) | 2009-08-26 |
Family
ID=51359501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007001452A PE20091224A1 (en) | 2007-08-06 | 2007-10-25 | PHARMACEUTICAL COMPOSITION IN THE FORM OF ENCAPSULATED POWDERS INCLUDING ORLISTAT AND ITS PREPARATION PROCEDURE |
Country Status (7)
| Country | Link |
|---|---|
| CL (1) | CL53426B (en) |
| CR (1) | CR10132A (en) |
| DO (1) | DOP2008000021A (en) |
| MX (1) | MX2008010082A (en) |
| PA (1) | PA8786701A1 (en) |
| PE (1) | PE20091224A1 (en) |
| SV (1) | SV2009002991A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL216542B1 (en) * | 2008-03-20 | 2014-04-30 | Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna | Production method of a stable Orlistat composition in form of encapsulated powder |
-
2007
- 2007-08-06 CL CL2007002287A patent/CL53426B/es active
- 2007-10-25 PE PE2007001452A patent/PE20091224A1/en active IP Right Grant
-
2008
- 2008-04-10 DO DO2008000021A patent/DOP2008000021A/en unknown
- 2008-07-01 PA PA20088786701A patent/PA8786701A1/en unknown
- 2008-07-07 CR CR10132A patent/CR10132A/en not_active Application Discontinuation
- 2008-07-31 SV SV2008002991A patent/SV2009002991A/en unknown
- 2008-08-06 MX MX2008010082A patent/MX2008010082A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| MX2008010082A (en) | 2009-04-17 |
| CL2007002287A1 (en) | 2007-12-14 |
| SV2009002991A (en) | 2009-04-16 |
| CL53426B (en) | 2016-11-28 |
| PA8786701A1 (en) | 2009-04-23 |
| CR10132A (en) | 2008-10-28 |
| DOP2008000021A (en) | 2009-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA97489C2 (en) | Pharmaceutical composition containing amorphous rosuvastatin calcium | |
| GT200600194A (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING IMATINIB AND A PROLONGED RELEASE COMPONENT | |
| MX2010004897A (en) | Orally disintegrated dosage form. | |
| PE20201496A1 (en) | COMPOSITIONS AND METHODS TO TREAT ANEMIA | |
| EA029081B9 (en) | Combination formulation of two antiviral compounds | |
| HRP20211752T1 (en) | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof | |
| PE20030602A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING A MACROLIDE | |
| DE602005020655D1 (en) | Carboxamide-spirolactam CGRP Receptor Antagonists | |
| UA104869C2 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING Dopamine Receptor Ligands | |
| NO20085110L (en) | Substituted spirocyclic CGRP receptor antagonists | |
| RU2008135718A (en) | COMPOSITIONS OF BISULPHATE CLOPIDOGEL | |
| RU2010128019A (en) | ORAL DISPERSABLE TABLET | |
| MY147641A (en) | Fast release paracetamol tablets | |
| CR9953A (en) | DIARILURE FOR THE TREATMENT OF PULMONARY HYPERTENSION | |
| UA99136C2 (en) | Improved pharmaceutical composition comprising a calcium channel antagonist such as lercanidipine, process for the preparation thereof | |
| EP1861399A4 (en) | CGRP RECEPTOR ANTAGONISTS | |
| DK1996160T3 (en) | Controlled release bioresorbable composition | |
| IN2012DN02502A (en) | ||
| EA201171399A1 (en) | METHOD AND COMPOSITION FOR IMPROVING SUCTION OF MEDICINES | |
| SG178975A1 (en) | Indenone derivative and pharmaceutical composition comprising same | |
| AR077546A1 (en) | FORMULATIONS OF TABLETS OF 3-CYANOQUINOLINE AND USES OF THE SAME | |
| AR061093A1 (en) | CALCIUM COMPOSITIONS | |
| HRP20100120T1 (en) | Valsartan formulations | |
| ES2922903T3 (en) | Pharmaceutical composition comprising salts of lenvatinib | |
| PE20091224A1 (en) | PHARMACEUTICAL COMPOSITION IN THE FORM OF ENCAPSULATED POWDERS INCLUDING ORLISTAT AND ITS PREPARATION PROCEDURE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |